Interventions and Clinical Trials

In the News

‘Let’s do more to end malaria for good’

Dar es Salaam, November 29, 2017. Ifakara Health Institute (IHI) Chief Executive Director (CED), Dr. Honorati Masanja, has challenged scientists and other partners in the global fight against malaria to …

Joint statement: Scientists update on residual malaria situation

Dar es Salaam, November 29, 2017. The Residual Malaria Transmission workshop enters the second day today. The workshop, which is scheduled to end tomorrow, discusses findings of research projects investigating …

Recent Projects

Understanding and enhancing approaches to quality improvement in small and medium sized private facilities in sub-Saharan Africa

This is an evaluation study that IHI is conducting in collaboration with London school of hygiene and tropical medicine. The research takes place in the context of an innovative intervention …

Vaccine Delivery Costing Study

As countries drive towards achieving high and equitable coverage of life-saving vaccines, the availability of sustainable, equitable, and predictable financing for vaccine delivery is essential. Over the last two decades, …


The department conducts trials on drugs, diagnostics and vaccines for Tuberculosis (TB), HIV, Malaria and other diseases including respiratory pathogens,  zoonotic diseases, arboviruses, and various emerging and re-emerging infections. The department is supported by two laboratories with state of the art facilities at Ifakara and Bagamoyo Branches. The department is also expanding its portfolio to include non-communicable diseases, which are on the rise even in developing countries. Though we were previously working mostly on malaria, we have in recent years began work on development and testing of new TB drugs, given that what we have today have been in use for over 50 years. At our Chronic Diseases Clinic in Ifakara, we offer high quality HIV clinical care, while at the same time training researchers to improve the clinical care of HIV-infected people.  Moreover, IHI laboatories are continuously improving the diagnostic capacity, to serve IHI research projects and collaborators both within and outside the country. Our immunology department has grown in human capacity and equipment to analyze samples for different TB and malaria clinical trials.

In recent years scientists in the department have pioneered multiple innovative ways to assess vaccine candidates on malaria challenge study with infectious sporozoites. We are currently also providing technical support in other countries to start and implementing clinical trials. For example, we have a group now based in Equitorial Guinea supporting large-scale vaccine trial programs there. The department strives to strengthen the capacity to conduct clinical trials on infectious diseases including training IHI staff at Masters and PhD level. IHI is now firmly established as a dependable site where trials could be conducted in the future. The department staff are multidisplinary, consisting of statisticians, physicians, epidemiologists, public health specialists and social scientists.

Key Contacts

Head of Department

Deputy Heads of Department

Administrative Support


Evaluation of Cepheid GeneXpert Omni combined with the Xpert MTB/RIF Ultra in Primary Health Care in Tanzania

Evaluation of whole sporozoite vaccines for malaria elimination

Safety and immunogenicity of direct venus inoculation of Plasmodium falciparum sporozoite vaccine in adults, children and infants

Safety, immunogenicity and efficacy of intravenously administered attenuated Plasmodium falciparum sporozoite vaccine

Providers’ compliance to malaria treatment using Artemisinin-based combination therapy-ACTs in Tanzania

Evaluation of intravenous iron supplementation compared to oral supplementation among women with iron-deficient anemia

Zoonotic viral sharing among bats, primates and people in high-risk areas in Tanzania

Evaluation of Lopinavir-based anti-retroviral therapy for HIV-Infected children: a phase IIIb clinical trial in Ifakara

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

Screening and treatment of cryptococcal meningitis in Kilombero and Ulanga districts in Tanzania

Kilombero and Ulanga antiretroviral cohort study (KIULARCO)

Tanzania lung health study: prevalence and risk of chronic obstructive pulmonary disease

Malaria in Pregnancy Preventive Alternative Drugs(MiPPAD)

Epidemiology and molecular monitoring of HIV drug resistance in Tanzania

© Ifakara Health Institute (IHI), 2016